Phase 2 Study of NE3107 in Patients with Dementias
Key Findings and Practical Solutions
NE3107, an oral, anti-inflammatory, insulin-sensitizing molecule, showed positive effects in patients with mild cognitive impairment or mild dementia.
Practical Solutions:
- NE3107 was associated with improvements in cerebral blood flow and brain functional connectivity.
- Patients showed improvements in cognitive assessments, including ADAS-Cog11, Clinical Dementia Rating, Quick Dementia Rating Scale, Alzheimer’s Disease Composite Score, and Global Rating of Change.
- NE3107 demonstrated evidence of improvement in biomarkers associated with neuroinflammation and Alzheimer’s disease.
Value:
- Our results support the potential of NE3107 in positively impacting neurophysiological and neuropsychological findings in patients with dementia.
- NE3107 highlights the central role of neuroinflammation in Alzheimer’s disease pathogenesis.
Learn more about how our AI-driven platform, DocSym, and mobile apps can streamline operations and improve patient outcomes at aidevmd.com.
